I-DXd binds B7-H3 (not topoisomerase I), is internalized, and releases a deruxtecan topoisomerase I inhibitor that causes DNA damage. Cells are killed if they receive payload via B7-H3 targeting or bystander uptake; topoisomerase I is the intracellular enzymatic target, not the direct binding target.